|
KMID : 1148920080420000046
|
|
Nuclear Medicine and Molecular Imaging
2008 Volume.42 No. 0 p.46 ~ p.51
|
|
|
The Role of 18F-fluorodeoxyglucose Positron Emission Tomography in Gastrointestinal Stromal Tumors
|
|
Yoo Ie-Ryung
|
|
|
Abstract
|
|
|
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal neoplasm of the gastrointestinal tract, and can be distinguished from the smooth muscle or neural tumors in approximately 95% of patients by expression of the KIT receptor tyrosine kinase (CD117). GISTs are known to have high malignant potential and none can be labeled definitely as benign. However, GISTs are unresponsive to standard sarcoma chemotherapy, and only complete surgical resection provides chance for cure. Although the imaging modality of choice is enhanced CT scan in patients with GIST, FDG PET can reflect the malignant potential of GIST. Clinical management of patients with GISTs has dramatically changed with the
introduction of novel therapeutics, such as imatinib mesylate (Glivec). This has created a need to re-evaluate the existing criteria used to assess treatment response. FDG PET as functional imaging modality proved to be significantly more accurate than CT alone when assessing GIST response to imatinib. And, FDG PET and PET/CT have been found to be highly sensitive in detecting early response, and to be useful in predicting long-term response to imatinib in patients with recurrent or metastatic GISTs. (Nucl Med Mol Imaging 2008;42(suppl 1):46-51)
|
|
|
KEYWORD
|
|
|
Gastrointestinal stromal tumor, 18F-FDG, PET
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|